Akers Biosciences, Inc.
(NASDAQ GS: AKER)
Rigrodsky & Long is investigating Akers Biosciences, Inc. (“Akers”) regarding possible breaches of fiduciary duties and other violations of law related to Akers' agreement to merge with MYMD Pharmaceuticals, Inc. ("MYMD"). Under the terms of the agreement, Akers will issue a number of shares of Akers' common stock to shareholders of MYMD. Upon completion of the merger, Akers' shareholders will own approximately 20% of the combined company and MYMD's shareholders will own approximately 80% of the combined company.